Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Mar 04, 2024 11:50am
145 Views
Post# 35913432

RE:Year end financials

RE:Year end financials

The year end financials & outlooks & updates are all legally mandated reports.
Basically a rear view mirror look @ what has happened so far.
With managements comments on expectations going forward.
Any " news" ...meaning something of substance like a buyout or partership, could happen anytime.
Such as later today, a few days before Thursday , or months after.
point?
the required reportings are just that. Rarely do they announce anything substantial at a Scheduled update.
" news" like we all want to hear, will come on its own timeline. 

That being when contracts are signed & ready for shareholders approval vote.
saying all that, they sure need to up the game between now & Thursday.
pancreatic phase 3 pathway?
certainly needs explanation 
stay tuned
 

<< Previous
Bullboard Posts
Next >>